PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo et al., 2008
GH SecretagoguesResearch OnlyD
Mod GRF 1-29
CJC-1295 (no DAC) / GRF 1-29
Short-acting GHRH analog used in research protocols for pulsatile GH signaling.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 2
- Research grade
- D
- Experience
- 99
- Activity
- 73
Overall check-ins
Trackers & reports
Overview
About Mod GRF 1-29
Short-acting GHRH analog used in research protocols for pulsatile GH signaling.
- Category
- GH Secretagogues
- Regulatory status
- Research Only
- Also known as
- CJC-1295 (no DAC) / GRF 1-29
- Self-reports
- 27
Community
What 27 users report
27 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Sleep
160
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
4
Self-reported dose per injection
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 100–400 mcg
100–200
100
200–400
60
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 91% said they felt similar to their last entry, 9% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 170 days · Based on 23 repeat reporters
Research
Cited research (1)
Source
Tools
Explore more
Explore
More ways to learn about Mod GRF 1-29 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Mod GRF 1-29?
This page summarizes 27 anonymized self-reports from PeptIQ users who track Mod GRF 1-29, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Mod GRF 1-29?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Mod GRF 1-29?
1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Mod GRF 1-29 safe to use?
This wiki does not assess safety or recommend use. Mod GRF 1-29 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Mod GRF 1-29?
This wiki summarizes observational community reports and linked citations for Mod GRF 1-29. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for Mod GRF 1-29 for study-level context — not medical advice.
What is the legal status of Mod GRF 1-29?
Mod GRF 1-29 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of Mod GRF 1-29?
Safety data quality for Mod GRF 1-29 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on Mod GRF 1-29?
This page links 1 indexed sources for Mod GRF 1-29. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.